| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g | |||
| 10g | |||
| Other Sizes |
| Targets |
β-lactam
Cefaclor exerts its antibacterial activity by binding to and inactivating penicillin-binding proteins (PBPs), particularly penicillin-binding protein 3 (PBP3). This binding inhibits the transpeptidase activity of PBPs, preventing the cross-linking of peptidoglycan chains, which is essential for bacterial cell wall integrity. This leads to cell lysis and bacterial death. |
|---|---|
| ln Vitro |
Cefaclor is active against a wide range of commonly encountered bacterial pathogens. As a second-generation cephalosporin, it has enhanced activity against Gram-negative bacteria compared to first-generation agents. Its in vitro activity is consistent with its mechanism of inhibiting bacterial cell wall synthesis.
|
| ln Vivo |
Cefaclor is a well-absorbed orally active cephalosporin antibiotic used to treat certain bacterial infections such as pneumonia and infections of the ear, lung, skin, throat, and urinary tract. Its in vivo efficacy is established through its clinical use.
|
| Enzyme Assay |
Cefaclor's antibacterial activity is assessed using standard in vitro microbiological susceptibility testing methods. Minimum inhibitory concentration (MIC) determinations are performed against various bacterial strains. The compound's binding affinity to penicillin-binding proteins (PBPs), particularly PBP3, can be evaluated using competitive binding assays.
|
| Cell Assay |
Cellular assays for cefaclor are conducted using standard microbiological techniques with bacterial cultures. The compound's antibacterial activity is evaluated by determining the minimum inhibitory concentration (MIC) against various bacterial strains. Bacterial growth inhibition is assessed by measuring optical density or by counting colony-forming units.
|
| Animal Protocol |
In vivo animal model protocols for cefaclor would involve its oral administration to animal models of infection to evaluate its efficacy. Studies may include models of pneumonia, ear, lung, skin, throat, and urinary tract infections. The compound's oral bioavailability makes it suitable for outpatient treatment models.
|
| ADME/Pharmacokinetics |
Cefaclor is a well-absorbed orally active cephalosporin antibiotic. It has a molecular weight of 385.82 and a molecular formula of C15H16ClN3O5S. It is soluble in water and practically insoluble in methanol, chloroform, and benzene. Solutions are stable at pH 2.5-4.5.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Cefaclor has been discontinued in the United States. Limited information suggests that low concentrations of cefaclor in breast milk are not expected to have adverse effects on breastfed infants after mothers have taken the medication. There have been reports that cephalosporins occasionally disrupt the infant's gut microbiota, leading to diarrhea or thrush, but these effects have not been fully assessed. It is safe for breastfeeding women to take cefaclor. ◉ Effects on Breastfed Infants In a telephone follow-up study, five breastfeeding mothers reported taking cefaclor (dosage not specified). One mother reported her infant developing diarrhea. No rashes or candidiasis were reported in infants exposed to cefaclor. ◉ Effects on Lactation and Breast Milk As of the revision date, no relevant published information was found. Cefaclor is generally well-tolerated. Common side effects associated with cephalosporins include gastrointestinal disturbances and hypersensitivity reactions, particularly in patients with penicillin allergy. Cefaclor is a frequent inducer of serum sickness-like reactions. |
| References | |
| Additional Infomation |
Cefaclor is a second-generation β-lactam cephalosporin antibiotic with bactericidal activity. Cefaclor binds to and inactivates penicillin-binding protein (PBP) located on the bacterial cell membrane. PBP is an enzyme involved in the late stage of bacterial cell wall assembly and cell wall remodeling during growth and division. PBP inactivation interferes with the cross-linking of peptidoglycan chains, which is crucial for maintaining the strength and rigidity of the bacterial cell wall. This leads to weakening of the bacterial cell wall, ultimately resulting in cell lysis. Cefaclor is a semi-synthetic broad-spectrum antibiotic derivative of cefalexin. See also: Cefaclor (note moved to).
Cefaclor monohydrate (CAS# 70356-03-5) is a semisynthetic second-generation cephalosporin antibiotic for oral administration. It is active against a wide range of bacterial pathogens and is used to treat pneumonia and infections of the ear, lung, skin, throat, and urinary tract. |
| Molecular Formula |
C15H16CLN3O5S
|
|---|---|
| Molecular Weight |
385.8226
|
| Exact Mass |
385.05
|
| Elemental Analysis |
C, 46.70; H, 4.18; Cl, 9.19; N, 10.89; O, 20.73; S, 8.31
|
| CAS # |
70356-03-5
|
| Related CAS # |
Cefaclor;53994-73-3
|
| PubChem CID |
51038
|
| Appearance |
Off-white to light yellow solid powder
|
| Boiling Point |
713.4ºC at 760 mmHg
|
| Melting Point |
>180ºC (dec.)
|
| Flash Point |
385.2ºC
|
| LogP |
1.586
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
606
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
ClC1C([H])([H])S[C@]2([H])[C@@]([H])(C(N2C=1C(=O)O[H])=O)N([H])C([C@@]([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])[H])=O.O([H])[H]
|
| InChi Key |
WKJGTOYAEQDNIA-IOOZKYRYSA-N
|
| InChi Code |
InChI=1S/C15H14ClN3O4S.H2O/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7;/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23);1H2/t9-,10-,14-;/m1./s1
|
| Chemical Name |
(6R,7R)-7-((R)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate
|
| Synonyms |
Ceclor; Keclor; S6472; S-6472; S 6472; LS-149967; LS149967; LS 149967;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~11 mg/mL ( ~28.51 mM ）
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5919 mL | 12.9594 mL | 25.9188 mL | |
| 5 mM | 0.5184 mL | 2.5919 mL | 5.1838 mL | |
| 10 mM | 0.2592 mL | 1.2959 mL | 2.5919 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
